SSG
TARS icon

Summit Securities Group’s Tarsus Pharmaceuticals TARS Stock Holding History

Summit Securities Group’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.9K Buy
+634
New +$40.5K ﹤0.01% 616
2025
Q1 		– Sell
-157
Closed -$8.69K – 1092
2024
Q4 		$8.69K Buy
+157
New +$7.13K ﹤0.01% 478

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Summit Securities Group's TARS Position: Q2 2026 in Review

Summit Securities Group opened a new position in Tarsus Pharmaceuticals (TARS) in Q2 2026: 634 shares worth $39.9K. The stake represents ﹤0.01% of the portfolio and ranks #616 among its holdings. This is a return to the name: Summit Securities Group previously reported a position in TARS as recently as Q4 2024.

Summit Securities Group first reported a position in TARS in Q4 2024 and has held it in 2 quarters since. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Summit Securities Group held 634 shares of Tarsus Pharmaceuticals worth $39.9K as of Q2 2026.
  • Tarsus Pharmaceuticals was a new Summit Securities Group position in Q2 2026.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Summit Securities Group's portfolio in Q2 2026, its #616 holding.
  • Summit Securities Group first reported a position in Tarsus Pharmaceuticals in Q4 2024 and has held it in 2 quarters since.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.